相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
已完成
1
100.0%
<p><strong>Indications</strong></p> <p>OPSYNVI® is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 inhibitor (PDE5i) indicated for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) in adult patients of WHO functional class (FC) II–III.</p>
<p><strong>Indications</strong></p> <p>OPSYNVI® is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 inhibitor (PDE5i) indicated for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) in adult patients of WHO functional class (FC) II–III.</p>
<p><strong>Indications</strong></p> <p>TALVEY®, as monotherapy, is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.</p>
<p><strong>Indications</strong></p> <p>TALVEY®, as monotherapy, is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.</p>
<p><strong>Indications</strong><br> <strong>Plaque Psoriasis:</strong><br> STELARA® is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate or PUVA.</p> <p><strong>Pediatric Plaque Psoriasis:</strong><br> STELARA® is indicated for the treatment of pediatric patients (children and adolescents) (6 years and older) with moderate to severe plaque psoriasis who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</p> <p><strong>Psoriatic Arthritis (PsA):</strong><br> STELARA®, alone or in combination with methotrexate (MTX), is indicated for:</p> <ul> <li>the treatment of adult patients (18 years or older) with active psoriatic arthritis when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate</li> <li>inhibiting the progression of structural damage</li> </ul> <p><strong>Crohn’s Disease:</strong><br> STELARA® is indicated for the treatment of adults with moderately to severe active Crohn’s disease who have:</p> <ul> <li>failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed treatment with a tumor necrosis factor (TNF) blocker or</li> <li>failed or were intolerant to treatment with one or more TNF blockers</li> </ul> <p><strong>Ulcerative Colitis:</strong><br> STELARA® is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.</p>
<p><strong>Indications</strong></p> <p>TECVAYLI® as monotherapy is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.</p>
<p><strong>Indications</strong></p> <p>TECVAYLI® as monotherapy is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.</p>
<p><strong>Indications</strong></p> <p>INVEGA HAFYERA®, a 6-month injection, is indicated for the treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.</p>
暂无资讯文章
